Media-News

Be the most trusted biotech company

2026-05-23

Henlius’ Serplulimab Receives Positive CHMP Opinion for the Treatment of sqNSCLC
2026-05-23

Henlius' First-in-Class B7-H3–Targeted Sialidase Fusion Protein HLX316/E-688 Administered to First Patient in Phase 1 Study in China
2026-05-22

ASCO 2026: Henlius’ Serplulimab Unveils 8 Major Studies, Highlighted by the Global Debut of Perioperative Gastric Cancer Data with Significant Improvement in EFS and pCR Rate of 21.6%
2026-05-22

Henlius' STEAP1×CD3×CD28 Trispecific TCE HLX3902 Approved for Clinical Trial in Australia，Showing Potential Against Cold Tumours
2026-05-21

Henlius Announces IND Approval from NMPA for Its Proprietary c-Met/EGFR Bispecific ADC HLX48
2026-05-21

Global Development Accelerates Further: Henlius' PD-L1 ADC HLX43 Completes First Patient Dosing in EU for Phase 2 MRCT
2026-05-19

ESTRO 2026 | Henlius' Serplulimab Achieves 42.5% pCR Rate in Neoadjuvant Colon Cancer; Study Results Presented Orally
2026-05-14

Accelerating Global Progress | Henlius' Serplulimab Japan Bridging Study for First-Line SCLC Completes Enrolment
2026-05-13

Henlius' potential BIC oral KAT6A/B inhibitor HLX97 completes first patient dosing in Phase 1, aiming to overcome endocrine therapy resistance in breast cancer